{"id":"dextromethorphan-oral-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"88137097-16b3-44b7-8e1f-26a8242d8179","title":"PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION SOLUTION [PREFERRED PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dextromethorphan suppresses the cough center in the medulla oblongata through NMDA receptor antagonism and sigma-1 receptor modulation. It is a non-narcotic alternative to codeine-containing cough syrups and does not produce analgesia or significant respiratory depression at therapeutic doses. The drug is rapidly metabolized to dextrorphan, which contributes to its pharmacological effects.","oneSentence":"Dextromethorphan is a non-opioid cough suppressant that acts as an antagonist at the NMDA receptor and sigma-1 receptor to reduce cough reflex.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:10:39.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cough suppression in upper respiratory tract infections and other conditions causing cough"}]},"trialDetails":[{"nctId":"NCT06566794","phase":"NA","title":"KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2024-08-22","conditions":"Drug Interaction","enrollment":12},{"nctId":"NCT06716645","phase":"PHASE4","title":"A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin","status":"COMPLETED","sponsor":"HALEON","startDate":"2024-12-04","conditions":"Common Cold, Cough","enrollment":244},{"nctId":"NCT05334108","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport","status":"COMPLETED","sponsor":"Emalex Biosciences Inc.","startDate":"2022-04-26","conditions":"Drug Interaction","enrollment":56},{"nctId":"NCT05236530","phase":"PHASE1","title":"Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-09","conditions":"Malaria","enrollment":48},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT04764851","phase":"PHASE1","title":"Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates","status":"TERMINATED","sponsor":"Emalex Biosciences Inc.","startDate":"2021-02-18","conditions":"Drug-Interactions","enrollment":30},{"nctId":"NCT02760615","phase":"PHASE4","title":"Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":""},{"nctId":"NCT03213353","phase":"PHASE1","title":"A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2017-07-03","conditions":"Bioequivalence, Healthy Volunteers","enrollment":72},{"nctId":"NCT03563287","phase":"NA","title":"Effects of LRYGB on Pharmacokinetics of Nine CYP Probe Drugs","status":"COMPLETED","sponsor":"University of Eastern Finland","startDate":"2012-01-27","conditions":"Obesity, Morbid, Bariatric Surgery Candidate","enrollment":13},{"nctId":"NCT03381664","phase":"PHASE1","title":"Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Avanir Pharmaceuticals","startDate":"2017-11-28","conditions":"Healthy Adult Male and Female Volunteers","enrollment":17},{"nctId":"NCT03195946","phase":"PHASE1","title":"Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2017-06-16","conditions":"Drug Reactions","enrollment":24},{"nctId":"NCT00467779","phase":"PHASE1","title":"Study of Cobimetinib in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-05","conditions":"Solid Tumor","enrollment":119},{"nctId":"NCT02243553","phase":"PHASE1","title":"Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-01","conditions":"Healthy","enrollment":34},{"nctId":"NCT02182336","phase":"PHASE1","title":"Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-06","conditions":"Healthy","enrollment":23},{"nctId":"NCT01766050","phase":"PHASE4","title":"Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-01","conditions":"Transplant Rejection","enrollment":45},{"nctId":"NCT00726726","phase":"PHASE1","title":"Drug Interaction Study With a Potential Alzheimer's Disease Compound","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-08","conditions":"Alzheimer Disease","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rometor Ratiopharm 2 mg/ml oral solution, Ratiopharm"],"phase":"marketed","status":"active","brandName":"Dextromethorphan Oral Solution","genericName":"Dextromethorphan Oral Solution","companyName":"Helsinki University Central Hospital","companyId":"helsinki-university-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dextromethorphan is a non-opioid cough suppressant that acts as an antagonist at the NMDA receptor and sigma-1 receptor to reduce cough reflex. Used for Cough suppression in upper respiratory tract infections and other conditions causing cough.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}